Top Tweets for #BioLogic
What if you could detect #biologic instability before it becomes a costly development problem? ARGEN yields real-time stability insights that help accelerate #biologics development—reducing risk, minimizing iterations, & a faster path to manufacturing. 🎥 See ARGEN in action!
A self-controlled case series to evaluate the effects of clinical trial eligibility #criteria on #biologic-associated #reductions in severe #asthma #exacerbations: an analysis of the CHRONICLE Study. https://t.co/JiDlBiL6XW
“[My #doctor] predicted in 2022 that I’d be a patient who needs #biologic swapping therapy every 6 months to a year and he has been right. This is why I’ve been through so many #medications.”: https://t.co/XaXY1pSwg7 by @globetrotteri #ChronicIllness #AutoimmuneDisease #AxSPA
Now available on demand on @medliveofficial
This expert-led #CME program explores type 2 inflammation and eosinophils in #COPD and offers practical, guideline-based strategies to individualize care, including the use of emerging #biologic therapies.
▶️https://t.co/52h1XujDzZ
Infographic: Beyond the Clinic: Are We Underestimating #Asthma #Biologic #Adherence? https://t.co/Xrj15kgUVo
Going from a medium-dose #inhaled #corticosteroid to a #biologic for #asthma led to significant decreases in #exacerbations, according to a poster presented at the American Academy of #Allergy, Asthma & #Immunology Annual Meeting. https://t.co/5e6d2H1PkN
"Rheuminococcus gnavus #bacteria may be associated with #lupus and #LupusNephritis. Treating R. gnavus could limit the need for #biologic or DMARD therapy in some patients with lupus": https://t.co/Shx5GA172e via @GoHealio
#MedicalResearch #GutMicrobe #autoimmune #ChronicIllness
#WAOJournal: Indication for #biologic #treatment in a real-world cohort of #chronic #rhinosinusitis patients according to international recommendations: Evidence from the European CRS outcome registry (CHRINOSOR). Open Access. https://t.co/NSQagMdG9U
‘There’s still something we are missing’ - #biologics #underused in #multinational #survey: less than 15% of adults with #uncontrolled #asthma eligible for #biologic #therapy reported current biologic use, according to survey data. https://t.co/nrQgLsUFDy
Two new #WAO committee papers published: “What is new on the horizon for the #biologic therapies world: New treatments at the starting blocks” and "World Allergy Organization survey on the diagnosis and management trends of #perioperative #anaphylaxis".
https://t.co/2TADGV9Ssp
#Women with #spondyloarthritis (SpA) show markedly shorter persistence on first and second #biologic #DMARDs (bDMARDs) despite similar initiation timing, as demonstrated by real-world data from Spanish REGISPONSER/REGISPON-3 registry:
◦ Study population: 411 SpA patients (271 males, 140 females) followed for 17 years (REGISPONSER → REGISPON-3).
◦ bDMARD initiation: No significant sex difference in time to first bDMARD (from symptoms or diagnosis).
◦ Males showed significantly longer persistence (retention) on bDMARD therapy compared to females:
- First bDMARD: males 88 months vs females 48 months (p = 0.004)
- Second bDMARD: males 260 months vs females 133 months (p = 0.0007)
◦ Multivariable analyses (Cox proportional hazards models) revealed sex-specific predictors of bDMARD initiation.
◦ The main reason for discontinuation was inefficacy in both sexes, but adverse events were reported more frequently as a reason for stopping treatment in females.
These findings indicate that while the timing of starting bDMARDs is similar between males and females with SpA, women demonstrate significantly shorter persistence on biological treatments over the long-term follow-up.
*Moldovan DMM, Ladehesa-Pineda L, Puche-Larrubia MÁ et al. Sex-based differences in bDMARD initiation and persistence in spondyloarthritis: a 17-year follow-up study from the REGISPON-3 registry. Rheumatology (Oxford). Published online March 21, 2026.
🔗https://t.co/P2UVjRv2pP
#Pregnant women with vs. without an #asthma #biologic #prescription had a significantly lower likelihood for #adverse #pregnancy #outcomes, according to findings published in The Journal of Allergy and Clinical Immunology: In Practice.
https://t.co/FPnzT3XilM
Wow the first 24 hours of this new #Biologic is hitting hard. I cant sleep the symptoms are so rough. So I cant help but watch #JudgeJudy. Reminds me of times I was a kid and watch with my mom. Long night ahead!
To inform clinicians on the best #biologic agent for different populations of adults with severe #asthma, 12 experts collaborated on a new @accpchest clinical practice guideline.
💬Healio spoke with Amber J. Oberle, MD, and @fholguinmd to learn more.
https://t.co/N5DDwdnvb3
“[I didn't] think my current primary #biologic is controlling my #disease. I’ve been battling #edema everywhere: my face, chest, arms & legs for over a year. It’s very disturbing to see what it has done to my #body.”: https://t.co/wHc5wNMOjR by @globetrotteri #ChronicIllness
Last Seen Hashtags on Sotwe
dìcháu
Seen from Vietnam
สาวใหญ่โคราช
Seen from Thailand
artist
Seen from United States
حصري_الرياض
Seen from Egypt
manisa
Seen from Turkey
ไซด์ไลน์ชัยภูมิ
Seen from Thailand
RoughSex
Seen from Saudi Arabia
craftycorn
Seen from United States
สงขลาfwb
Seen from Thailand
rr34 sona
Seen from United States
Trends for you
Most Popular Users
Elon Musk 
@elonmusk
240.2M followers
Barack Obama
@barackobama
119.3M followers
Donald J. Trump
@realdonaldtrump
111.6M followers
Cristiano Ronaldo
@cristiano
109.2M followers
Narendra Modi
@narendramodi
106.9M followers
Rihanna
@rihanna
97.3M followers
NASA
@nasa
92.1M followers
Justin Bieber
@justinbieber
90.6M followers
KATY PERRY
@katyperry
87M followers
Taylor Swift
@taylorswift13
80.8M followers
Lady Gaga
@ladygaga
72.3M followers
Kim Kardashian
@kimkardashian
69.5M followers
Virat Kohli
@imvkohli
68.8M followers
YouTube
@youtube
68.6M followers
Bill Gates
@billgates
63.5M followers
The Ellen Show
@theellenshow
62.5M followers
CNN
@cnn
61.9M followers
Neymar Jr
@neymarjr
61.4M followers
X
@x
60.9M followers
Selena Gomez
@selenagomez
60.1M followers